Valuation: AP Biosciences, Inc.

Market Cap 11.9B 367M 326M 302M 275M 518M 34.84B 529M 3.63B 1.42B 18.15B 1.38B 1.35B 57.97B P/E 2024
-8.86x
P/E 2025 -34.4x
Enterprise Value 10.79B 333M 296M 274M 249M 470M 31.59B 479M 3.29B 1.29B 16.45B 1.25B 1.22B 52.56B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
52.82%
Yield 2024 *
-
Yield 2025 -
1 week-8.27%
Current month-17.85%
1 month+11.42%
3 months+8.93%
6 months-37.11%
Current year-32.22%
1 week 120
Extreme 120
133.5
1 month 114
Extreme 114
149
Current year 86.1
Extreme 86.1
236
1 year 86.1
Extreme 86.1
236
3 years 36.3
Extreme 36.3
236
5 years 36.3
Extreme 36.3
236
10 years 36.3
Extreme 36.3
236
Manager TitleAgeSince
Chief Executive Officer - 27/05/2013
Director of Finance/CFO - 18/10/2022
Chief Administrative Officer - 18/10/2022
Director TitleAgeSince
Director/Board Member - 09/11/2022
Director/Board Member - 04/06/2019
Director/Board Member - 04/06/2021
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-8.27%+19.61%+131.50% 367M
-6.60%-10.93%+45.08%+60.01% 68.98B
-4.09%+3.12%+3.71%+53.50% 53.15B
+0.03%+7.21%+12.52%+44.46% 50.83B
-1.53%+3.10%+31.40%+33.88% 44.61B
-5.97%-5.40%+259.08%+494.98% 40.57B
-1.34%+5.41%+16.74%+106.42% 42.53B
+6.53%+8.02%+18.98%+54.58% 30.95B
-0.90%-10.91%+34.11%-1.83% 25.44B
-2.76%-4.73%-15.94%-15.32% 22.66B
Average -1.48%+1.09%+42.53%+96.22% 38.01B
Weighted average by Cap. -2.32%+1.65%+46.48%+96.57%

Financials

2024 2025
Net sales - -
Net income -423M -13.04M -11.58M -10.72M -9.77M -18.41M -1.24B -18.78M -129M -50.6M -645M -48.92M -47.88M -2.06B -445M -13.72M -12.19M -11.28M -10.28M -19.37M -1.3B -19.76M -136M -53.23M -678M -51.47M -50.37M -2.17B
Net Debt -1.47B -45.35M -40.3M -37.3M -33.98M -64.04M -4.31B -65.33M -449M -176M -2.24B -170M -167M -7.17B -1.11B -34.27M -30.46M -28.19M -25.68M -48.4M -3.25B -49.37M -339M -133M -1.69B -129M -126M -5.41B
Projected Income Statement - Annual - AP Biosciences, Inc.
Logo AP Biosciences, Inc.
AP Biosciences Inc is a Taiwan-based company mainly engaged in the research and development of protein drugs and antibody drugs. The Company develops early candidate drugs and preclinical trials, and develops different monoclonal or bispecific antibody drugs for potential targets, mechanisms of action, and disease characteristics through drug design and existing technology platforms. The Company's technology platform and bispecific protein drug research and development projects include IBI302-anti-vascular endothelial growth factor (VEGF) and anti-complement bifunctional recombinant protein, OmniMab fully human antibody library, AP505-PD-L1 x VEGF bispecific antibody, target-directed T cell activation 3T platform (T-cube), AP203-PD-L1 x CD137 fully human bispecific antibody, and others.
Employees
-
Date Price Change Volume
16/10/26 TWD 122.00 0.00% 133,433
15/10/26 TWD 122.00 -0.41% 294,644
14/10/26 TWD 122.50 -0.81% 161,757
13/10/26 TWD 123.50 -1.59% 262,154
12/10/26 TWD 125.50 -5.64% 436,227
  1. Stock Market
  2. Stocks
  3. 6945 Stock